Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

87.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
BioMarin needs to run additional testing in animal models for its PKU gene therapy. 
Via Investor's Business Daily
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN... 
Via Benzinga
BioMarin Sells Priority Review Voucher For $110M
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
Futures Resume Tumbling After Yields Spike To New 2 Year High
US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am. 
Via Talk Markets
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe... 
Via Benzinga
This Favorable Sign Appears On Biomarin Pharmaceutical's Chart
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not... 
Via Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not... 
Via Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Monday
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo. 
Via The Motley Fool
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
BioMarin Stock Jumps As FDA Approval Unlocks Its 'Next Growth Inflection'
The BioMarin drug treats achondroplasia, a form of short-limbed dwarfism. 
Via Investor's Business Daily
Exposures Product Safety
FDA Conditionally Approves Biomarin's Dwarfism Drug
The FDA has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia... 
Via Benzinga
Exposures Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
BioMarin's Q3 Net Income Hit By Lower Product Sales
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million. The decline... 
Via Benzinga
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript
BMRN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biomarin Pharmaceutical: Q3 Earnings Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Stifel 
Via Benzinga
Exposures Product Safety
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene... 
Via Benzinga
Exposures Product Safety
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The... 
Via Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
All it will take is an FDA approval and a partial repeat of history. 
Via The Motley Fool
Exposures Product Safety
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.